LAU-7b as next-generation COVID-19 therapeutic - COVID-19 Response-Stage 3 (TI): antiviral & Inflammation Controlling Therapeutic Drug Clinical Evaluation
$7,000,000.00
Grant Value
2024-25
Fiscal Year
Description
###############################################################################################################################################################################################################################################################
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Laurent Pharmaceuticals Inc.
Operating as: Laurent Thérapeutiques
Location
Montreal, QC H3A 2R7
Agreement Details
Number: 1002706
Reference: 172-2022-2023-Q4-1002706
Timeline
Start: Feb. 1, 2023
End: March 31, 2025
Program
Industrial Research Assistance Program – Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share